118 related articles for article (PubMed ID: 7671094)
21. The role of IGF-I and its binding proteins in the development of type 2 diabetes and cardiovascular disease.
Ezzat VA; Duncan ER; Wheatcroft SB; Kearney MT
Diabetes Obes Metab; 2008 Mar; 10(3):198-211. PubMed ID: 18269635
[TBL] [Abstract][Full Text] [Related]
22. [Hormones and osteoporosis update. Growth hormone and bone].
Tanaka H
Clin Calcium; 2009 Jul; 19(7):984-9. PubMed ID: 19567995
[TBL] [Abstract][Full Text] [Related]
23. Insulin like growth factors and their importance in pediatrics.
Philipps AF
Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi; 1996; 37(1):1-10. PubMed ID: 8936003
[TBL] [Abstract][Full Text] [Related]
24. Insulin-like growth factors and pancreas beta cells.
van Haeften TW; Twickler TB
Eur J Clin Invest; 2004 Apr; 34(4):249-55. PubMed ID: 15086355
[TBL] [Abstract][Full Text] [Related]
25. Off-label use of exenatide for the management of insulin-resistant type 1 diabetes mellitus in an obese patient with human immunodeficiency virus infection.
Sheffield CA; Kane MP; Busch RS
Pharmacotherapy; 2007 Oct; 27(10):1449-55. PubMed ID: 17896900
[TBL] [Abstract][Full Text] [Related]
26. Study of insulin resistance in relation to serum IGF-I levels in treated type-II diabetic patients.
Srinivas M; Narayana P; Surender T; Krishna DR
J Assoc Physicians India; 2008 Aug; 56():645-6. PubMed ID: 19054866
[No Abstract] [Full Text] [Related]
27. Insulin resistance is associated with increased serum concentration of IGF-binding protein-related protein 1 (IGFBP-rP1/MAC25).
López-Bermejo A; Khosravi J; Fernández-Real JM; Hwa V; Pratt KL; Casamitjana R; Garcia-Gil MM; Rosenfeld RG; Ricart W
Diabetes; 2006 Aug; 55(8):2333-9. PubMed ID: 16873698
[TBL] [Abstract][Full Text] [Related]
28. Is there a medical need to explore the clinical use of insulin-like growth factor I?
Savage MO; Camacho-Hübner C; Dunger DB; Ranke MB; Ross RJ; Rosenfeld RG
Growth Horm IGF Res; 2001 Jun; 11 Suppl A():S65-9. PubMed ID: 11527091
[TBL] [Abstract][Full Text] [Related]
29. [Amylin as an additional possible pathogenic factor in NIDDM and the insulin resistance syndrome].
Hrnciar J
Vnitr Lek; 1996 Aug; 42(8):557-60. PubMed ID: 8967027
[TBL] [Abstract][Full Text] [Related]
30. [Does insulin glargin (lantus) lead to a progression in diabetic retinopathy?].
Meyer CH; Kroll P; Hammes HP
Klin Monbl Augenheilkd; 2005 Apr; 222(4):353-4. PubMed ID: 15844050
[No Abstract] [Full Text] [Related]
31. Does IGF-I therapy in insulin-dependent diabetes mellitus limit complications?
Møller N; Orskov H
Lancet; 1997 Oct; 350(9086):1188-9. PubMed ID: 9652553
[No Abstract] [Full Text] [Related]
32. Does recombinant insulin-like growth factor I have a role in the treatment of insulin-dependent diabetes mellitus during adolescence?
Dunger DB; Cheetham TD; Holly JM; Matthews DR
Acta Paediatr Suppl; 1993 Mar; 388():49-52; discussion 53. PubMed ID: 8329831
[No Abstract] [Full Text] [Related]
33. Risks and benefits of insulin-like growth factor.
Burguera B
Ann Intern Med; 1994 Oct; 121(7):549; author reply 550. PubMed ID: 8067658
[No Abstract] [Full Text] [Related]
34. Insulin-like growth factor-I for the treatment of type 1 diabetes.
Acerini CL; Dunger DB
Diabetes Obes Metab; 2000 Dec; 2(6):335-43. PubMed ID: 11225962
[No Abstract] [Full Text] [Related]
35. Insulin-like growth factor-I: a treatment for type 2 diabetes revisited.
Murphy LJ
Endocrinology; 2006 Jun; 147(6):2616-8. PubMed ID: 16707730
[No Abstract] [Full Text] [Related]
36. The therapeutic potential of recombinant human insulin-like growth factor-I.
Cotterill AM
Clin Endocrinol (Oxf); 1992 Jul; 37(1):11-5. PubMed ID: 1424187
[No Abstract] [Full Text] [Related]
37. Insulin-like growth factor-I in the therapy of non-insulin-dependent diabetes mellitus and insulin resistance.
Froesch ER; Bianda T; Hussain MA
Diabetes Metab; 1996 Jul; 22(4):261-7. PubMed ID: 8767173
[TBL] [Abstract][Full Text] [Related]
38. Diabetes and Atherosclerosis: Old Players in a New Field, Osteoporosis.
Paschou SA; Anagnostis P; Vryonidou A; Goulis DG
Curr Vasc Pharmacol; 2018; 16(6):524-527. PubMed ID: 29210657
[No Abstract] [Full Text] [Related]
39. Catabolic hormones and growth hormone resistance in acquired immunodeficiency syndrome and other catabolic states.
Rodgers BD
Proc Soc Exp Biol Med; 1996 Sep; 212(4):324-31. PubMed ID: 8751989
[No Abstract] [Full Text] [Related]
40. Insulin, cation metabolism and insulin resistance.
Sowers JR; Draznin B
J Basic Clin Physiol Pharmacol; 1998; 9(2-4):223-33. PubMed ID: 10212836
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
